Cargando…

Novel Dermal Delivery Cargos of Clobetasol Propionate: An Update

Dermal disorders such as psoriasis and eczema are associated with modifications in the chemical and molecular composition of the skin. Clobetasol propionate (CP), a superpotent topical glucocorticoid, is widely used for the therapeutic management of various skin conditions, owing to its strong anti-...

Descripción completa

Detalles Bibliográficos
Autores principales: Nair, Anroop B., Kumar, Sunil, Dalal, Pooja, Nagpal, Chahat, Dalal, Sweta, Rao, Rekha, Sreeharsha, Nagaraja, Jacob, Shery
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877216/
https://www.ncbi.nlm.nih.gov/pubmed/35214115
http://dx.doi.org/10.3390/pharmaceutics14020383
_version_ 1784658367477710848
author Nair, Anroop B.
Kumar, Sunil
Dalal, Pooja
Nagpal, Chahat
Dalal, Sweta
Rao, Rekha
Sreeharsha, Nagaraja
Jacob, Shery
author_facet Nair, Anroop B.
Kumar, Sunil
Dalal, Pooja
Nagpal, Chahat
Dalal, Sweta
Rao, Rekha
Sreeharsha, Nagaraja
Jacob, Shery
author_sort Nair, Anroop B.
collection PubMed
description Dermal disorders such as psoriasis and eczema are associated with modifications in the chemical and molecular composition of the skin. Clobetasol propionate (CP), a superpotent topical glucocorticoid, is widely used for the therapeutic management of various skin conditions, owing to its strong anti-inflammatory, antipruritic, vasoconstrictive, and antiproliferative activities. Safety studies demonstrated that CP is safer for a shorter period, however, with prolonged application, it shows secondary side effects such as photosensitivity, Cushing-like syndrome, allergic contact dermatitis, osteonecrosis, hypopigmentation, steroid acne, and skin atrophy. Therefore, the US FDA (United States Food and Drug Administration) has restricted the usage of CP to not more than 15 days. Research scientists addressed its several formulations and drug delivery issues, such as low water solubility, less stability, photodegradation, and poor absorption, by incorporating them into novel nanobased delivery platforms. With the utilization of these technologies, these drawbacks of CP have been resolved to a large extent to reestablish this moiety. This article explores the physicochemical properties and mechanism of action of CP. Additionally, an attempt has been made to discover and highlight the possible features of the novel nanosystems, including nanoemulsions, nanosponges, solid lipid nanoparticles, nanostructured lipid carriers, and nanogels, reported for CP. The stability and safety concerns of CP, along with its commercial status, are also discussed.
format Online
Article
Text
id pubmed-8877216
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88772162022-02-26 Novel Dermal Delivery Cargos of Clobetasol Propionate: An Update Nair, Anroop B. Kumar, Sunil Dalal, Pooja Nagpal, Chahat Dalal, Sweta Rao, Rekha Sreeharsha, Nagaraja Jacob, Shery Pharmaceutics Review Dermal disorders such as psoriasis and eczema are associated with modifications in the chemical and molecular composition of the skin. Clobetasol propionate (CP), a superpotent topical glucocorticoid, is widely used for the therapeutic management of various skin conditions, owing to its strong anti-inflammatory, antipruritic, vasoconstrictive, and antiproliferative activities. Safety studies demonstrated that CP is safer for a shorter period, however, with prolonged application, it shows secondary side effects such as photosensitivity, Cushing-like syndrome, allergic contact dermatitis, osteonecrosis, hypopigmentation, steroid acne, and skin atrophy. Therefore, the US FDA (United States Food and Drug Administration) has restricted the usage of CP to not more than 15 days. Research scientists addressed its several formulations and drug delivery issues, such as low water solubility, less stability, photodegradation, and poor absorption, by incorporating them into novel nanobased delivery platforms. With the utilization of these technologies, these drawbacks of CP have been resolved to a large extent to reestablish this moiety. This article explores the physicochemical properties and mechanism of action of CP. Additionally, an attempt has been made to discover and highlight the possible features of the novel nanosystems, including nanoemulsions, nanosponges, solid lipid nanoparticles, nanostructured lipid carriers, and nanogels, reported for CP. The stability and safety concerns of CP, along with its commercial status, are also discussed. MDPI 2022-02-09 /pmc/articles/PMC8877216/ /pubmed/35214115 http://dx.doi.org/10.3390/pharmaceutics14020383 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Nair, Anroop B.
Kumar, Sunil
Dalal, Pooja
Nagpal, Chahat
Dalal, Sweta
Rao, Rekha
Sreeharsha, Nagaraja
Jacob, Shery
Novel Dermal Delivery Cargos of Clobetasol Propionate: An Update
title Novel Dermal Delivery Cargos of Clobetasol Propionate: An Update
title_full Novel Dermal Delivery Cargos of Clobetasol Propionate: An Update
title_fullStr Novel Dermal Delivery Cargos of Clobetasol Propionate: An Update
title_full_unstemmed Novel Dermal Delivery Cargos of Clobetasol Propionate: An Update
title_short Novel Dermal Delivery Cargos of Clobetasol Propionate: An Update
title_sort novel dermal delivery cargos of clobetasol propionate: an update
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877216/
https://www.ncbi.nlm.nih.gov/pubmed/35214115
http://dx.doi.org/10.3390/pharmaceutics14020383
work_keys_str_mv AT nairanroopb noveldermaldeliverycargosofclobetasolpropionateanupdate
AT kumarsunil noveldermaldeliverycargosofclobetasolpropionateanupdate
AT dalalpooja noveldermaldeliverycargosofclobetasolpropionateanupdate
AT nagpalchahat noveldermaldeliverycargosofclobetasolpropionateanupdate
AT dalalsweta noveldermaldeliverycargosofclobetasolpropionateanupdate
AT raorekha noveldermaldeliverycargosofclobetasolpropionateanupdate
AT sreeharshanagaraja noveldermaldeliverycargosofclobetasolpropionateanupdate
AT jacobshery noveldermaldeliverycargosofclobetasolpropionateanupdate